ERBB2, erb-b2 receptor tyrosine kinase 2, 2064

N. diseases: 995; N. variants: 85
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group BEFREE An examination of HER2 and NF-κB receptor (RANK) coexpression revealed increased levels of both proteins in aggressive prostate tumors and metastatic deposits. 27793843 2017
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE Previous work in animal models showed that p110α was the key isoform in breast tumors driven by oncogenes, including MT and HER2, while p110β was key in prostate tumors driven by Pten loss. 24991009 2014
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group BEFREE Both wild-type and mutant forms of plexinB1 are potential targets for anti-cancer therapy in prostate tumors that express ErbB2. 23775445 2013
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE Pharmacological inhibition of ErbB2 and c-Met reduced the ability of prostate tumor progenitor cells to undergo self-renewal in vitro. 23348745 2013
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group BEFREE In this study, we show that patients who develop prostate tumors with low levels of PTEN and high levels of HER2/3 have a poor prognosis. 21930937 2011
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group LHGDN Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. 18767028 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group LHGDN CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. 18337451 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN Human epidermal growth factor receptor type 2 protein expression in Chinese metastatic prostate cancer patients correlates with cancer specific survival and increases after exposure to hormonal therapy. 18645672 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group LHGDN The subset of prostate tumors with increased HER-2/neu and AR levels may benefit from treatment strategies that target both signaling pathways. 18324648 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group CTD_human Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. 17363613 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE In the sc implanted human prostate tumors (22Rv-1) in nude mice, AN-7 significantly inhibited Ki-67, HIF-1alpha, HER-2/neu, bFGF and increased PTEN level. 17611019 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN Wwox suppresses prostate cancer cell growth through modulation of ErbB2-mediated androgen receptor signaling. 17704139 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group LHGDN Her2/neu expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients. 18038879 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN ErbB-2 via PYK2 upregulates the adhesive ability of androgen receptor-positive human prostate cancer cells. 17563746 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE A hypothetical protein H41 was detected, which may repress the Her-2/neu receptor influencing breast cancer, gliomas and prostate tumors. 17192923 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. 16984552 2006
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group CTD_human Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. 16984552 2006
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 GeneticVariation group LHGDN Association of HER-2 polymorphism with Japanese sporadic prostate cancer susceptibility. 15389808 2005
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 GeneticVariation group BEFREE Of the 10 tumor samples analyzed by fluorescence in situ hybridization, genomic amplification of the Her-2/neu locus was not detected in any of the metastatic prostate tumors. 15269147 2004
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE Peripheral blood lymphocytes (PBL) were then isolated from six consecutive human leukocyte antigen (HLA) A2+ patients with HER2/neu+ prostate tumors. 15547716 2004
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE In order to define AR, erbB-1 and erbB-2 in human prostate neoplasms 36 benign prostatic hyperplasia, 46 prostatic carcinoma and 12 normal prostate gland samples were analysed. 14654929 2004
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 GeneticVariation group LHGDN Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. 15083213 2004
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 GeneticVariation group LHGDN The expression level was similar in all prostate tumor types and corresponded to the level of expression in breast carcinomas without ERBB2 amplification. 11786427 2002
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group BEFREE To quantitate the level of ERBB2 mRNA expression in prostate tumors (n = 34) and cell lines (n = 3), as well as in breast tumors (n = 30) and cell lines (n = 16), real-time reverse transcriptase-polymerase chain reaction (LightCycler) methodology was used. 11786427 2002
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group BEFREE Previous studies have reported widely divergent rates for HER2 expression in primary prostate tumors, probably owing to significant methodologic differences in the studies. 11488070 2001